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INTRODUCTION
Clostrodium difficile is ubiquitous in nature and
has been isolated from soil, water, and stool of many
healthy infant but from the stool from only about 3%
of healthy adult volunteers. In a minority of the
population, C. difficile is a normal intestinal flora, which
can be part in as many as 50-80 % of healthy neonatus,
and less frequently (3%) in individuals over two years
of age. C. difficile is a species of bacteria of
the genus Clostridium which are gram-positive,
anaerobic, spore-forming rods, motile, and
characteristic obligate anaerob. The species was
named “difficile” because initially it was difficult to
culture. Under the microscope after Gram staining,
they appear as long drumsticks with a bulge located at
their terminal ends (figure 1). C. difficile has
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ABSTRACT
Clostridium difficile is the most important cause of antibiotic associated diarrhea, and
pseudomembranous colitis, a severe infection of the colon. Strain Clostridium difficile produce two
potent toxin, toxin A (enterotoxin) and toxin B (cytotoxin). These two toxins are both responsible for
the diarrhoea and inflammation seen in patients treated due to infection, especially the broad spectrum
antibiotics. Direct detection of Clostridium difficile cytotoxin from faecal specimen using mammalian
tissue culture lines is considered the standard diagnostics test of Clostridium difficile infection. This test is
very sensitive but requires a minimum two days to complete. In order to improve the threshold of diagnosis
and treatment, a number of enzyme immunoassay methods have been used, with a reported sensitivity to
either toxin A or toxin B.
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characteristic antiphagositic polysaccharide capsule.
Toxigenic and non toxigenic strains exist.1-5
C. difficile virulence are related to fimbriae,
flagella and polysaccharide capsule and exotoxin which
produced by it, especially the exotoxin. Toxigenic strains
of C. difficile produce two large toxins: toxin A is
a 308 kDa enterotoxin, ad toxin B is a 250/270 kDa
cytotoxin. Almost all toxigenic strains posses the genes
for, and produce both toxins. Some strains of
C. difficile are non toxigenic and it is generally
accepted that non toxigenic strains are also non
pathogenic strains. The strain which recommended has
the genes of toxin A and B is VPI 10463.5,7-11
However, recently, the types of strain which produce
toxin B but not toxin A have been described.11-12
In a recent report from Canada, an outbreak of
diarrhoea associated with Toxin A-B+ C. difficile.13
PATHOGENESIS AND PATHOPHYSIOLOGY
In most industrialized country, C. difficile is the first
organism suspected by health care personal when
a hospitalized patient developed diarrhoea. C. difficile
infection is a nosocomial disease that is spread
primarily by medical staff and hospital epidemics are
relatively common.1,14 Most cases of C. difficile
associated diarrhoea are acquired in hospital although
community acquired cases are increasingly being
reported.3
Figure 1. Gram stain of Clostridium difficile showing
characteristic Gram positive rods6
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The precipitating even for C. difficile colitis is
disruption of the normal colonic microflora.
This disruption usually is cost by broad spectrum
antibiotic, with clindamycin and broad-spectrum
penicillin and cephalosporins most commonly
implicated.4  However, the number of antibiotics
nor the duration of therapy was a factor in
predisposing patients to infection.15  The major host
factors predisposing patients to the development of
symptomatic C. difficile infection include advanced
age, number and severity of underlying disease, and
faulty immune response to C. difficile toxins.
Increasing rates of community-acquired C. difficile-
associated infection has also been linked to the use of
medication to suppress gastric acid production:
H2-receptor antagonists increased the risk twofold, and
proton pump inhibitors threefold, mainly in the elderly.
It is presumed that increased gastric pH leads to
decreased destruction of spores.4
Colonisation is thought to result from ingestion of
spores, which can survive in extreme environmental
condition and persist for months or years. Ingested
spores survive the acidity of the stomach and convert
to vegetative organism when they reach the colon.
The infected patients in hospital are an important
reservoir of the organism. Depending on host factors
an asymptomatic carrier state or clinical manifestation
of C. difficile colitis develop.4,7
C. difficile toxins binds to specific receptors to
stimulate fluid secretion and necrosis of the mucosa
associated with an inflammatory infiltrate.15 Toxin A
causes fluid secretion and mucosal damage, resulting
in diarrhoea and inflammation. Toxin B is a powerful
cytotoxin, 1000 times more potent in tissue cultures
than toxin A. Both toxin activate the release of cytokines
of human monocyte, and this effect may be
responsible for the colonic inflammation seen in
pseudomembranous colitis.5,9,16 The clinical
presentation ranges from mild diarrhoea to
life-threatening disease, such as fulminant
pseudo-membranous colitis and toxic megacolon
(figure 2).3,4
COLLECTION AND TRANSPORT OF SPECIMENS
CONTAINING C. DIFFICILE
The diagnosis is usually based on the analysis of
fresh diarrhoeic stool. The minimal volume of fresh
stool is about 5 to 50 millilitres or 5 to 50 grams.2
Well-formed stools and samples from patients younger
than one year of age should be rejected in the
laboratory unless an epidemiologic study of stool
carriage is being conducted.3,18 Other suitable
specimens include biopsy material or lumen contents
obtained by colonoscopy and involved bowel.
The samples have to be put in capped plastic container
for transport of the specimens and should be promptly
sent to the laboratory. The samples should be
examined in two hours, or could be stored in 4°C or
freeze. Toxin denaturation occurred if samples remain
at room temperature longer than two hours.2,8,11
However, for shipment of specimens to a reference
laboratory for a toxin assay, we recommend they be
shipped on dry ice. On the other hand, an anaerobic
transport container (transported at 25°C) should be used
for specimens to be processed for isolation and
identification of C. difficile. Specimens to be processed
for the latex agglutination test should not be frozen,
because the antigen detected is unstable on freezing.2
DIAGNOSIS LABORATORY
The laboratory method for the diagnosis of
C. difficile infection are essentially detection of the
organism and demonstration of its toxins.7 The assay
to detect the organism are culture and Gram stain,
common antigen detection using immunoassay method
(IA) or latex agglutination test, and polymerase chain
reaction (PCR) method. Immunoassay for detection
of C. difficile toxins sometimes combine with
common antigen detection, have become available.
Rapid staining techniques, such as Gram stain or
fluorescent antibodies are not recommended.3,19
The laboratory diagnosis of C. difficile infection
depends on toxin detection in diarrhoeal stool. It is
generally accepted that non toxigenic strains are also
non pathogenic strains.7 The gold standard test for
C. difficile infection is stool/tissue culture assay for
toxin B (CBA). In this test cell cultures are used to
demonstrate cytotoxicity in the presence of stool
extract, which is prevented by administration of
antitoxin. This test has excellent sensitivity and
specificity, and can detect toxin B concentrations as
low as 10 pg/mL.3,18-22
Cytotoxin B assay detect the presence of toxin B
in a cellular culture using cell line such as human lung
fibroblast (MRC-5), Chinese hamster ovary (CHO),
Vero, or Hep2. The standard procedure CBA is,
faecal specimens were prepared and according to each
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The supernatant was collected, then filtered through 
a 0.2 ìm pore size filter. Then inoculate the filtrate into  
cell monolayer and incubate within 24-48 hours.  
The principle of CBA is characteristic cytopathic  
effect (CPE) neutralized by antitoxin was interpreted  
as a positive result.3,4,11,18 However, it is also the least  
controlled test, and non specific reaction is common in  
some laboratories in the hands of an inexperienced  
technologist. The addition of too much faecal material  
to the tissue culture well can cause false positive  
reactions.1 Toxin B is a heat-labile protein; therefore,  
samples must be refrigerated immediately upon  
collection. The CBA take 24 to 48 hours to complete,  
and some hospitals may not have an in-house tissue  
culture facility, which can delay diagnosis. CBA test  
could be perform on the sample of culture colony, called  
“cytotoxin culture assay”. This method can increase  
the sensitivity up to 99% with the longer time  
consuming (72-92 hours) and more expensive.3,18-19,23  
 Recently, the most common laboratory test for  
diagnosis C. difficile-mediated disease is an enzyme  
immunoassay that detects toxin A, the combination of  
toxin A  and B, or the common antigen in one kit.1,4  
This test provide quick result and less expensive too.  
These systems have a good specificity, but their  
sensitivity is low, as they cannot detect quantities of  
toxin below 100-1000 pg. Therefore, there is a false  
negative rate of 10 - 20 %.3,18 Those that detect both  
toxin A and toxin B are preferred than detect only toxin  
A. For A-B+ strains are capable of spreading and  
causing outbreaks and fatal disease, the recommended  
assay is the test that can detect both toxin.1,3  
The principle of procedure of EIA is, during the first  
incubation, C. difficile toxin A + B present in stool  
supernatant are captured by antibodies attached to  
the wells. The second incubation adds additional  
antitoxin A + B antibodies that sandwiches 
the antigen. The next incubation adds an anti-second  
antibody conjugated to peroxidase. After washing to  
remove unbound enzyme, a chromogen is added which  
develops a blue colour in the presence of the enzyme  
complex and peroxide. The stop solution ends  
the reaction and turns the blue colour to yellow.21,,24  
The Infectious Diseases Society of America and  
The Society for Hospital Epidemiology of America have  
device guidelines for detecting C. difficile toxin  
(table 1).18 
C. difficile can be isolated by the use of spore 
selection technique (i.e. heat shock or alcohol  
selection procedures) and by use of selective plating  
media containing phenyl ethyl alcohol (PEA) blood agar,  
or cycloserine-cefoxitin, egg yolk and fructose agar  
(CCFA), and colonies may be identified by  
characteristic fluorescence. Presumptive colonies were  
characteristic by a yellowish colour, flat morphology,  
yellow-green fluorescence, and a horsey smell. CCFA  
plates were incubated anaerobically at 37°C for  
a minimum two days. In addition to spore selection  
procedure, a plate of PEA or CCFA medium should be  
inoculate with untreated stool or stool suspension  
prepared in buffered gelatine diluent. However,  
culture is not specific for pathogenic toxin-producing  
C. difficile strains and, therefore is not clinically  
 helpful except for strain typing in outbreaks of  
nosocomial infection as well as epidemiologic and 
clinical research.2,4,11,21,25-26 
Some commercial test for common antigen of  
C. difficile, specific glutamate dehydrogenase (GDH)  
has been available for more than 10 years. The initial  
kit on the market was latex agglutination test, but  
a lateral device with coloured latex conjugate and  
flowthrough tests with enzyme conjugates have  
become available. GDH is an essential enzyme and is  
produced constitutively by all C. difficile isolates. Like  
bacterial culture, test that detect common antigen  
do not distinguish toxin-producing from non-toxigenic  
isolates. Even so, the common antigen has proven to  
be a good screening marker for C. difficile because  
the enzyme is produced in large amounts and can readily  
be detected in faecal specimens. The commercial  
GDH tests offer a turn-around time of 15 to 45  
minutes, which is another reason the test are used in  
laboratory. The greatest utility of the common antigen  
tests is their use as a screen to rule specimens  
negative and to select specimens for further testing, a  
toxin test. A combination immunoassay for GDH and  
toxin A and toxin B have become available with a high  
sensitivity (97%) and specificity (97 to 99%). 
The advantages of this test are same day turn-around  
and high negative predictive value.1,4,19  
 The tissue damage to the intestinal mucosa by  
toxins A and B leads to a rapid influx of inflammatory  
cells. The inflammatory response plays a key role in  
how quickly the disease progress es to colitis and  
whether the disease develops into pseudomembranous  
colitis, which is life-threatening if left untreated.  
Levels of faecal lactoferrin, which is released from  
the secondary granules of faecal leukocytes and other  
inflammatory markers rise significantly in patients with  
advanced C. difficile disease compared with levels in  
patients with milder case of the disease. Thus,  
the presence of elevated faecal lactoferrin may help  
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Table 1. Guidelines for the use of the Clostridium difficile toxin 
assay18 
Only diarrheal stools should be tested unless there is ileus 
“A test of cure” should not be performed except as part of an 
epidemiologic investigation 
Only specimens from patients who are older than one year of age 
should be tested 
Enzyme immunoassay is an acceptable alternative to the cytotoxin 
assay but is less sensitive 
Diarrhea that develops after three days of hospitalization should be 


















to define the severity of the disease. Tests that 
monitor the level of intestinal inflammation will provide 
valuable information to physicians, alerting them to the 
need for prompt therapy with metronidazole and 
vancomycin when there is inflammation in 
the presence of the organism.1,27 
The Polymerase Chain Reaction (PCR) has been  
used to detect C. difficile in stool specimens and to  
identify toxigenic strains among isolates, and directly  
from primary culture plates, by using primers based on  
the genes for toxin A and toxin B. These method are  
highly specific and sensitive, but further work on  
the direct detection on C. difficile and its toxin in stool  
samples is needed before they can be used routinely.7  
Simon et al28 report the first real time PCR assay for  
detection of C. difficile. It is a rapid, sensitive, and  
specific and allows detection of C. difficile directly  
from stool samples. 
There are some characteristic of the main 




Toxin A (enterotoxin) and toxin B (cytotoxin) of  
Clostridium difficile are both responsible for the  
diarrhoea and inflammation in patients treated  
especially with the broad spectrum antibiotics. Direct  
detection of C. difficile cytotoxin from faecal  
specimen using mammalian tissue culture lines is  
considered the standard diagnostics test of C. difficile  
infection. However, it is also the least controlled test,  
and non specific reaction is common in some  
laboratories in the hands of an inexperienced  
technologist and some hospitals may not have  
an in-house tissue culture facility, which can delay  
diagnosis. 
In order to improve the threshold of diagnosis and  
treatment, a number of Elisa immunoassay method  
have been used. The most common laboratory test for  
diagnosis C. difficile-mediated disease is an enzyme  
immunoassay that detects toxin A, the combination of  
toxin A and B, or the common antigen in one kit. This  
test provides fast result, less expensive, and has a good  
specificity, although their sensitivity is relatively low. 
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